10x Genomics, Inc. (TXG) SEC Filings & Earnings Calls

Patent litigation exposure

“The company is involved in multiple patent lawsuits, including with Illumina, Element, and Spatial Genomics, which could result in adverse outcomes.”

Revenue concentration on license settlements

“License and royalty revenue fell from $27.8 million in Q2 2025 to $1.9 million in Q2 2026, indicating lumpy, non-recurring revenue.”

Patent litigation settlement revenue is non-recurring and volatile, impacting comparability.

“Excluding $1.6 million and $27.3 million of non-recurring revenue related to patent litigation settlements in the second quarter of 2026 and 2025, respectively.” · word for word

Patent litigation uncertainty

“The Company is regularly subject to lawsuits, claims, arbitration proceedings, administrative actions and other legal and regulatory proceedings involving intellectual property disputes... As of March 31, 2026, the Company has concluded that a loss is not probable and a contingent liability has not been recorded.” · word for word

Instrument revenue decline

“Instruments revenue decreased $3.6 million, or 24%, to $11.3 million for the three months ended March 31, 2026 as compared to the three months ended March 31, 2025.” · word for word

Dependence on non-recurring license revenue

“License and royalty revenue decreased $16.1 million, or 94%, in the three months ended March 31, 2026 as compared to the three months ended March 31, 2025. The decrease was primarily due to one-time royalty revenue of $16.8 million recognized in the three months ended March 31, 2025 in connection with our worldwide patent litigation settlement with Vizgen.” · word for word

Revenue decline due to one-time license and royalty revenue in prior year.

“Revenue was $150.8 million for the first quarter of 2026, a 3% decrease from the corresponding period of 2025. Excluding $16.8 million related to a patent litigation settlement recognized in the first quarter of 2025, revenue increased 9%” · word for word

NIH Funding Disruption

“In February 2025, the NIH imposed a standard indirect rate of 15% across all NIH grants for indirect costs... the situation remains uncertain and our customers may face increased financial pressure due to this change or any future caps on indirect costs.” · word for word

China Trade Restriction

“If China were to expand the Unreliable Entity List to include other life sciences companies including 10x, our business in China, which represented approximately ten percent of our total revenue in 2025, could be materially impacted or eliminated.” · word for word

Inventory Obsolescence

“we recorded charges of $26.5 million and $11.3 million in 2025 and 2024 related to excess and obsolete inventory.” · word for word

Tariff Cost Pressure

“We face increased costs due to tariffs imposed by the United States on materials we purchase, which may negatively impact our financial results.” · word for word

Core revenue declining 2% in FY25 and guided for only 0-4% growth in FY26 signals weak demand in life science tools market.

“FY25 revenue ex-litigation -2%; FY26 guidance $600-625M implies 0-4% growth ex-litigation”

Dependence on non-recurring litigation revenue masks underlying business weakness.

“$44.1M non-recurring revenue from patent litigation settlements in FY25”

Instruments revenue declining significantly (-36% YoY in Q4, -39% FY) may indicate market saturation or competitive pressure; reliance on consumables growth.

“Instruments revenue of approximately $15.5 million, representing 29% growth sequentially and a 36% decrease as compared to the corresponding prior year period.” · word for word

Patent litigation risk

“Parse filed petitions for Inter Partes Review ('IPR') of the 981, 197 and 013 patents which were found unpatentable by the Patent Trial and Appeals Board in February 2025. The Company strongly disagrees with those decisions and has appealed.” · word for word

Restructuring execution risk

“On May 6, 2025, the Company implemented a reduction in force plan in order to decrease costs and maintain a streamlined organization to support the business. Restructuring charges of $6.0 million associated with this plan, comprised primarily of severance-related costs, were recorded in the second quarter of 2025.” · word for word

Revenue decline and margin compression due to product mix and inventory write-downs. Q4 guidance implies continued YoY decline.

“Revenue -2% YoY, gross margin -300bps. Q4 guidance -6% YoY.”

Dependence on instrument sales which are declining.

“Revenue decrease primarily driven by a decrease in instrument revenue.”